Hormone Therapy and Radiotherapy for Intermediate Risk Prostate Cancer

Seminars in Radiation Oncology

Volumn 18, Issue 1, 2008, Pages 7-14

  Lee, Irwin ^a   Sandler, Howard ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN THERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; DISEASE DURATION; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; HORMONAL THERAPY; HOT FLUSH; HUMAN; LIBIDO DISORDER; LONG TERM CARE; MOOD CHANGE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT FAILURE;

ANDROGEN ANTAGONISTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; TIME FACTORS;

EID: 36849069845     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2007.09.002     Document Type: Article

References (32)

1. Kupelian P.A., Potters L., Khuntia D., et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 25-33
2. Huggins C., and Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 168 (2002) 9-12
3. Crook J., Ludgate C., Malone S., et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 60 (2004) 15-23
4. Joon D.L., Hasegawa M., Sikes C., et al. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 38 (1997) 1071-1077
5. Zietman A.L., Nakfoor B.M., Prince E.A., et al. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: An in vitro and in vivo study. Cancer J Sci Am 3 (1997) 31-36
6. Zietman A.L., Prince E.A., Nakfoor B.M., et al. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 38 (1997) 1067-1070
7. Lilleby W., Fossa S.D., Knutsen B.H., et al. Computed tomography/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation. Radiother Oncol 57 (2000) 195-200
8. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 277 (1997) 1445-1451
9. D'Amico A.V., Renshaw A.A., Sussman B., et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440-447
10. Lee A.K., Schultz D., Renshaw A.A., et al. Optimizing patient selection for prostate monotherapy. Int J Radiat Oncol Biol Phys 49 (2001) 673-677
11. Beard C., Schultz D., Loffredo M., et al. Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 66 (2006) 403-407
12. Lee I.H., Roberts R., Shah R.B., et al. Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 1059-1064
13. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
14. Stock R.G., Ho A., Cesaretti J.A., et al. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Int J Radiat Oncol Biol Phys 66 (2006) 389-394
15. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15 (1997) 1013-1021
16. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
17. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360 (2002) 103-106
18. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
19. Denham J.W., Steigler A., Lamb D.S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6 (2005) 841-850
20. Roach III M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
21. D'Amico A.V., Schultz D., Loffredo M., et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 284 (2000) 1280-1283
22. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292 (2004) 821-827
23. Valicenti R.K., Bae K., Michalski J., et al. Does adjuvant hormonal therapy improve freedom from biochemical relapse in prostate cancer patients receiving dose-escalated radiation therapy?. An analysis of RTOG 94-06. ASCO Prostate Cancer Symposium, Abstract 297, Orlando, FL, February 22-24 (2007)
24. Dearnaley D.P., Sydes M.R., Morgan R.C., et al. Early efficacy and late toxicity of escalated-over-standard-dose conformal radiotherapy with neo-adjuvant androgen suppression for men with localized prostate cancer: First results of MRC RT01 trial (ISRCTN47772397). ASCO Prostate Cancer Symposium, Abstract 295, Orlando, FL, February 22-24 (2007)
25. Stephens R.J., Dearnaley D.P., Cowan R., et al. The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: Data from the Medical Research Council RT01 trial (ISRCTN 47772397). BJU Int 99 (2007) 301-310
26. Shahinian V.B., Kuo Y.F., Freeman J.L., et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154-164
27. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
28. Gulley J.L., Figg W.D., Steinberg S.M., et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. J Urol 173 (2005) 1567-1571
29. Murthy V., Norman A.R., Shahidi M., et al. Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer. BJU Int 97 (2006) 476-479
30. Feigenberg S.J., Hanlon A.L., Horwitz E.M., et al. Long-term androgen deprivation increases grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 62 (2005) 397-405
31. Christie D., Denham J., Steigler A., et al. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. Radiother Oncol 77 (2005) 117-125
32. Valicenti R.K., Winter K., Cox J.D., et al. RTOG 94-06: Is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?. Int J Radiat Oncol Biol Phys 57 (2003) 614-620